123 related articles for article (PubMed ID: 38458013)
1. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
Dong R; Wang T; Dong W; Zhu H; Liu Q; Liang H; Chen X; Zhang B; Zhang X
Biomed Pharmacother; 2024 Apr; 173():116366. PubMed ID: 38458013
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
[TBL] [Abstract][Full Text] [Related]
3. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
4. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
6. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
7. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
[TBL] [Abstract][Full Text] [Related]
8. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
10. Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR.
Shao W; Zhu W; Lin J; Luo M; Lin Z; Lu L; Jia H; Qin L; Lu M; Chen J
Neoplasia; 2020 Jan; 22(1):1-9. PubMed ID: 31751859
[TBL] [Abstract][Full Text] [Related]
11. miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Xu WP; Liu JP; Feng JF; Zhu CP; Yang Y; Zhou WP; Ding J; Huang CK; Cui YL; Ding CH; Zhang X; Lu B; Xie WF
Gut; 2020 Jul; 69(7):1309-1321. PubMed ID: 31727683
[TBL] [Abstract][Full Text] [Related]
12. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
Qi F; Qin W; Zhang Y; Luo Y; Niu B; An Q; Yang B; Shi K; Yu Z; Chen J; Cao X; Xia J
J Exp Clin Cancer Res; 2021 Sep; 40(1):280. PubMed ID: 34479623
[TBL] [Abstract][Full Text] [Related]
13. BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
Zhuang N; Gu Z; Feng J; Chai Z; Shan J; Qian C
Cell Signal; 2023 Aug; 108():110722. PubMed ID: 37209973
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Streubel G; Schrepfer S; Kallus H; Parnitzke U; Wulff T; Hermann F; Borgmann M; Hamm S
Sci Rep; 2021 May; 11(1):9587. PubMed ID: 33953226
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
16. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
17. Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma.
Luo J; Li L; Zhu Z; Chang B; Deng F; Wang D; Lu X; Zuo D; Chen Q; Zhou J
Biomed Pharmacother; 2022 Oct; 154():113602. PubMed ID: 36029544
[TBL] [Abstract][Full Text] [Related]
18. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
[TBL] [Abstract][Full Text] [Related]
19. Dietary antioxidant quercetin overcomes the acquired resistance of Sorafenib in Sorafenib-resistant hepatocellular carcinoma cells through epidermal growth factor receptor signaling inactivation.
Zhang Z; Wu H; Zhang Y; Shen C; Zhou F
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):559-574. PubMed ID: 37490119
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
